Cyclization Process for Hematological Cancer Compound
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for efficient and scalable processes for preparing the compound (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, which is effective against hematological cancer cell lines, but existing methods are inadequate in terms of efficiency and scalability.
Innovation Solution
A process involving the cyclization of a compound of Formula (II) to produce a compound of Formula (I), followed by optional conversion to a salt, such as a besylate, hydrochloride, or methanesulfonic acid salt, using specific acids, solvents, and reaction conditions to achieve stable solid forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing synthesis methods are used, then the compound can be prepared, but the process is inefficient and not scalable
Solution Approach 1:
The synthesis process is divided into distinct modular steps: (a) cyclization of compound of formula II to form compound of formula I, (b) optional conversion to salt forms, and (c) optional solid form preparation. Each step can be independently optimized and scaled, resolving the contradiction between synthesis efficiency and scalability.
Solution Approach 2:
The patent specifies optimized reaction parameters including temperature ranges (0°C to reflux), solvent types (acetonitrile, methanol, ethanol, or mixtures), and acid catalysts (formic acid, acetic acid, or trifluoroacetic acid) that enable both efficient reaction progression and scalability. The cyclization step uses specific molar ratios and reaction conditions that can be maintained across different production scales.
2Ease of manufacture
If the compound is prepared in solution form, then synthesis is simpler, but therapeutic utility is reduced due to instability
Solution Approach 1:
The patent incorporates preliminary actions to ensure stability: (b) converting the compound to stable salt forms during synthesis, and (c) preparing stable solid forms. These preliminary stability-enhancing steps are integrated into the synthesis process itself, allowing simple solution-phase synthesis to proceed while pre-establishing stability for later therapeutic use.
Solution Approach 2:
The patent utilizes phase transitions from solution to solid state through controlled crystallization processes. The compound is synthesized in solution but then converted to stable solid crystalline forms through controlled precipitation and crystallization steps, maintaining synthesis simplicity while ensuring therapeutic stability through the solid state transition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process enables the production of stable solid forms of the compound, enhancing its therapeutic utility and scalability for treating hematological malignancies by providing a more efficient synthesis method.
Implementation Method 1
cyclizing a compound of Formula (II) to provide a compound of Formula (I)
Implementation Method 2
converting the compound of Formula (I) to a salt of the compound
Data Source
AI summary
Provided herein are processes for the preparation of (S)-2-(2,6-dioxopipelidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl) benzyl)amino)isoindoline-1, 3-dione, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof, which is useful for treating, preventing, and managing various disorders. Also provided are solid forms of various intermediates and products obtained from the processes.